Modus Therapeutics Holding AB appointed panel of key scientific advisors - Professor Eddie Weitzberg, Professor Lennart Lindbom and Professor Mats Wahlgren from the Karolinska Institutet - who will support the company's future development strategy for sevuparin for sepsis/septic shock and other conditions where systemic inflammation is involved. Lennart Lindbom is Professor of Physiology at the Department of Physiology and Pharmacology at Karolinska Institutet. He is an expert in microvascular physiology and discovered the protective effects of heparinoids in systemic inflammation and performed landmark preclinical studies to show the benefit of sevuparin. Eddie Weitzberg is Professor of Anesthesiology and Intensive care at Karolinska Institutet and Senior Consultant at the department of Perioperative Medicine and Intensive Care at Karolinska University Hospital in Stockholm. Mats Wahlgren is Professor of Infectious Disease Control at Karolinska Institutet. He is a co-inventor of sevuparin and pioneered human studies in micro-vascular diseases. He has also explored the uses of heparinoids in diseases that do not rely on the anti-coagulant features of these compounds.